Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE:BMY) announced that its supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for treating adults with active psoriatic arthritis has been accepted for review in four global regions, including the FDA with a target action date of March 6, 2026.
The applications are supported by positive results from the POETYK PsA-1 and POETYK PsA-2 clinical trials, where Sotyktu demonstrated significantly higher ACR20 response rates compared to placebo at Week 16. The drug maintained clinical response through Week 52 in the POETYK PsA-2 trial, with a safety profile consistent with previous studies.
If approved, Sotyktu would become the first TYK2 inhibitor for psoriatic arthritis. The drug was previously approved by the FDA in 2022 for moderate-to-severe plaque psoriasis and has shown durable efficacy across over 20,000 patient-years of experience.
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 INDEPENDENCE trial for Reblozyl® (luspatercept-aamt) did not meet its primary endpoint in treating myelofibrosis-associated anemia. Despite missing statistical significance (p=0.0674), the trial showed clinically meaningful improvements in red blood cell transfusion independence.
The study demonstrated positive secondary outcomes, including a higher number of patients achieving a 50% reduction in RBC transfusion burden and increased hemoglobin levels while maintaining transfusion independence. The safety profile remained consistent with previous findings across indications. Despite not meeting the primary endpoint, BMS plans to engage with FDA and EMA regarding potential marketing applications based on the overall positive clinical benefits observed.
Bristol Myers Squibb (NYSE:BMY) and Pfizer have announced a significant direct-to-patient program for their anticoagulant medication Eliquis® (apixaban). Starting September 8, 2025, eligible U.S. patients can purchase Eliquis directly through the Eliquis 360 Support program at a 40% discount from the current list price.
The program will provide direct shipping across all 50 states and Puerto Rico, offering simplified access and cost transparency. With over 15 million Americans prescribed Eliquis since launch, the medication has generated an estimated $3 billion in healthcare cost savings per 100,000 patients treated through reduced hospitalizations and rehabilitation needs.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval of significant label updates for its CAR T cell therapies Breyanzi and Abecma. The updates include reduced patient monitoring requirements and removal of REMS programs, reflecting increased confidence in the therapies' safety profiles.
Key changes include reduction of driving restrictions from 8 to 2 weeks and requirement to stay near healthcare facilities reduced from 4 to 2 weeks post-treatment. Currently, only 2 in 10 eligible patients receive cell therapy treatment due to logistical and geographic barriers.
BMS will work with over 150 treatment centers to implement these changes and expand into community cancer centers nationwide, aiming to increase accessibility to these potentially life-saving treatments.
Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11, 2025. The company will engage in a fireside chat starting at 10:00 a.m. ET. Both investors and the general public can access the session through the company's investor relations website at http://investor.bms.com. An archived recording of the session will be made available after its conclusion.